Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nm decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 fold » _ fold (Expand Search), 5 fold (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nm decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 fold » _ fold (Expand Search), 5 fold (Expand Search)
-
201
-
202
-
203
Binding sensogram (a) showing decrease in frequency of crystal immobilised with 1.5 M short aptamer exposed to different concentrations of heparanase.
Published 2013“…<p>Higher concentrations of heparanase exhibited a greater decrease in frequency. Binding and regeneration sensogram (b) for addition of 800 nM heparanase to a quartz crystal immobilised with 1.5 M short aptamer. …”
-
204
-
205
-
206
Bioavailable Soil Phosphorus Decreases with Increasing Elevation in a Subarctic Tundra Landscape
Published 2014“…Meadow soils did not have lower concentrations of Resin-P than heath soils, but they did have 2–fold and 1.5–fold higher concentrations of NaOH-extractable organic P and Residual P, respectively. …”
-
207
DTG mice have significantly decreased troponin I phosphorylation and Serca2 expression.
Published 2013“…<p>(A) Representative Western blots depicting no changes in the expression of phosphorylated protein kinase A (P-PKA) and decreased expression of phosphorylated troponin I (P-TnI) and Serca2. ß-tubulin was used as a loading control. …”
-
208
Metabolites which were (A) reversibly decreased and (B) reversibly increased with smoking.
Published 2014“…TG = triglyceride, CDP = cytidine-diphosphate, DG = diglyceride, PC = phosphatidylcholine, PS = phosphatidylserine, TG = triglyceride, PA = phosphatidic acid. Fold change ≥1.5; <i>p</i>-value≤0.05, x-axis = Log2 normalized abundance scale; Error bars represent 95% confidence; Significance values *≤0.05, **≤0.01, ***≤0.001.…”
-
209
Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity
Published 2017“…Sphingosine 1-phosphate (S1P) is a pleiotropic signaling molecule that interacts with its five G-protein coupled receptors (S1P<sub>1–5</sub>) to regulate cell growth and survival and has been implicated in a variety of diseases including cancer and sickle cell disease. …”
-
210
-
211
-
212
-
213
Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors
Published 2017“…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
-
214
WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression.
Published 2024“…Corresponding densitometry analysis is noted as protein fold expression compared to GAPDH for WT1, p<0.001(***), vFLIP(ns), LANA p<0.05(*), pAKT p<0.05(*), and BCL2 p <0.05(*) using two-sided, unpaired student t-tests. …”
-
215
-
216
-
217
(R)-albuterol decreases cytokine mRNA levels in activated T cells
Published 2011“…RNA was isolated. Levels of IL-2, IL-13 and IL-6 (A, B, C) were measured by real time PCR. …”
-
218
-
219
-
220
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”